Stoke Therapeutics (NASDAQ:STOK) Price Target Cut to $14.00 by Analysts at Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOKFree Report) had its price target decreased by Needham & Company LLC from $25.00 to $14.00 in a research note released on Tuesday, Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

STOK has been the topic of a number of other research reports. TD Cowen downgraded shares of Stoke Therapeutics from an outperform rating to a market perform rating in a research note on Tuesday, July 25th. HC Wainwright reaffirmed a buy rating and set a $35.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 8th. Cantor Fitzgerald reduced their price target on shares of Stoke Therapeutics from $18.00 to $14.00 and set an overweight rating on the stock in a research report on Tuesday, August 8th. Finally, Credit Suisse Group reaffirmed an outperform rating and set a $23.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, August 8th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus price target of $21.00.

Check Out Our Latest Report on Stoke Therapeutics

Stoke Therapeutics Stock Performance

Stoke Therapeutics stock opened at $4.85 on Tuesday. The stock has a fifty day moving average of $4.31 and a two-hundred day moving average of $7.76. The company has a market capitalization of $214.81 million, a price-to-earnings ratio of -1.92 and a beta of 0.45. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $14.00.

Stoke Therapeutics (NASDAQ:STOKGet Free Report) last issued its quarterly earnings results on Monday, August 7th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.06). The business had revenue of ($2.48) million during the quarter, compared to analyst estimates of $4.00 million. Stoke Therapeutics had a negative net margin of 679.83% and a negative return on equity of 52.94%. On average, analysts forecast that Stoke Therapeutics will post -2.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of STOK. Ensign Peak Advisors Inc purchased a new position in Stoke Therapeutics in the 1st quarter worth approximately $25,000. Point72 Hong Kong Ltd purchased a new position in Stoke Therapeutics in the 1st quarter worth approximately $27,000. Great West Life Assurance Co. Can grew its stake in Stoke Therapeutics by 46.7% during the 1st quarter. Great West Life Assurance Co. Can now owns 3,387 shares of the company’s stock valued at $28,000 after purchasing an additional 1,078 shares in the last quarter. UBS Group AG acquired a new stake in Stoke Therapeutics during the 3rd quarter valued at approximately $47,000. Finally, SG Americas Securities LLC acquired a new stake in Stoke Therapeutics during the 3rd quarter valued at approximately $53,000.

About Stoke Therapeutics

(Get Free Report)

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

See Also

Analyst Recommendations for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.